Skip to main content
Premium Trial:

Request an Annual Quote

Gregory Piatetsky-Shapiro, Mary Jane Cunningham, Jim Sullivan and Norman Pace


Gregory Piatetsky-Shapiro has joined the scientific advisory committee of AnVil Informatics, based in Lowell, Mass. Piatesky-Shapiro co-founded the Data Mining and Knowledge Discovery Journal and is currently the editor of KDnuggets News. He served as vice president and chief scientist at Xchange, a customer relationship management company.


Molecular Mining of Raleigh, NC, has appointed Mary Jane Cunningham as director of discoveries and Jim Sullivan as director of North American sales. Cunningham was previously director of pharmacogenomics at Genometrix. Sullivan joins MMC from Lion Bioscience where he headed up sales and business development in the Northeastern US.


Norman Pace, a biology professor at the University of Colorado at Boulder, has won a 2001 MacArthur Fellowship. Among other achievements, Pace developed techniques to analyze the phylogenetic relationship between microorganisms based on their rRNA genes.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.